OUTCOME OF THE BOARD MEETING HELD ON 3RD FEBRUARY, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shri Dinesh Mills' board, meeting on February 3, 2026, approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, with a clean limited review report from auditor R.K. Doshi & Co. LLP. The board reappointed Ms. Reshma Patel as Non-Executive Independent Director for another five-year term starting March 15, 2026, subject to shareholder approval. Remuneration terms for Chairman & MD Shri Bharatbhai Patel were renewed for the period April 1, 2026 to March 31, 2028. The company also approved an investment of about Rs. 70.72 lakh in 7,07,200 0.01% Optionally Convertible Non-Cumulative Preference Shares of its wholly owned subsidiary Fernway Technologies Ltd. The auditor's report highlighted the completed disposal of subsidiary Dinesh Remedies Limited (effective September 3, 2025) as an emphasis-of-matter item, with the conclusion unaltered.
Routine quarterly results announcement with no negative audit qualifications; the subsidiary disposal is already completed, and the preference share investment in Fernway is a small inter-group move. Shareholders should watch for shareholder approval on Ms. Reshma Patel's reappointment and the MD remuneration resolution at the next general meeting.